Investment Thesis
Akari Therapeutics is a pre-revenue pharmaceutical company experiencing severe financial distress with a critical liquidity crisis (current ratio 0.27x) and approximately 1.2 years of cash runway at current burn rates. The company posted -$14.5M net loss with -$2.5M operating cash burn, indicating ongoing operational non-viability without significant capital raises. While net losses improved 12.6% YoY, the fundamental financial position remains untenable for near-term survival.
Strengths
- No long-term debt outstanding - not overleveraged or constrained by debt service
- Net loss improving year-over-year - demonstrates reduced cash burn trajectory
- Positive stockholders equity ($14.4M) - not technically insolvent yet
Risks
- Critical liquidity crisis - current ratio of 0.27x indicates current liabilities exceed current assets by 3.7x, severe working capital deficit
- Pre-revenue model - no commercial revenue generation, entirely dependent on external funding or asset sales
- Immediate cash runway risk - $2.8M cash with $2.5M annual burn rate provides approximately 13.4 months of operations before depletion
- Severely negative returns - ROE of -100.5% and ROA of -42.7% destroying shareholder value
- Dilution risk - company likely requires immediate equity raises to survive, causing shareholder dilution
Key Metrics to Watch
- Cash balance and monthly burn rate - monitor for capital raise announcements or bankruptcy risk
- Revenue recognition or pipeline advancement announcements - any progress toward commercialization
- Changes to current ratio and working capital position - indication of solvency trajectory
Financial Metrics
Revenue
N/A
Net Income
-14.5M
EPS (Diluted)
$0.00
Free Cash Flow
-2.5M
Total Assets
33.9M
Cash
2.8M
Profitability Ratios
Gross Margin
N/A
Operating Margin
N/A
Net Margin
N/A
ROE
-100.5%
ROA
-42.7%
FCF Margin
N/A
Balance Sheet & Liquidity
Current Ratio
0.27x
Quick Ratio
0.27x
Debt/Equity
0.00x
Debt/Assets
57.6%
Interest Coverage
-157.58x
Long-term Debt
N/A
Disclaimer: This analysis is generated by AI based on publicly available SEC EDGAR filings.
It does not include stock price data and should not be considered financial advice.
All fundamental data is sourced from SEC public domain filings.
Always conduct your own research before making investment decisions.
Data Source: SEC EDGAR |
Analysis Date: 2026-05-20T07:20:51.215936 |
Data as of: 2026-03-31 |
Powered by Claude AI